SEK 2.42
(-13.57%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 | 13.68 Million SEK | 4.49% |
2023 | 13.1 Million SEK | 43.7% |
2022 | 9.11 Million SEK | 64.75% |
2021 | 5.53 Million SEK | 55.62% |
2020 | 3.55 Million SEK | -5.37% |
2019 | 3.75 Million SEK | 8.31% |
2018 | 3.46 Million SEK | 35.85% |
2017 | 2.55 Million SEK | -5.47% |
2016 | 2.7 Million SEK | 4.4% |
2015 | 2.58 Million SEK | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q4 | 13.68 Million SEK | -2.96% |
2024 Q3 | 14.1 Million SEK | -4.06% |
2024 Q2 | 14.7 Million SEK | -3.81% |
2024 Q1 | 15.28 Million SEK | 16.69% |
2023 Q3 | 11.33 Million SEK | -0.46% |
2023 Q2 | 11.38 Million SEK | 22.22% |
2023 FY | 13.1 Million SEK | 43.7% |
2023 Q4 | 13.1 Million SEK | 15.57% |
2023 Q1 | 9.31 Million SEK | 2.2% |
2022 Q1 | 8.93 Million SEK | 61.44% |
2022 Q2 | 8.01 Million SEK | -10.32% |
2022 Q3 | 8.6 Million SEK | 7.46% |
2022 Q4 | 9.11 Million SEK | 5.9% |
2022 FY | 9.11 Million SEK | 64.75% |
2021 Q1 | 3.68 Million SEK | 3.75% |
2021 FY | 5.53 Million SEK | 55.62% |
2021 Q4 | 5.53 Million SEK | 2.66% |
2021 Q3 | 5.39 Million SEK | 7.88% |
2021 Q2 | 4.99 Million SEK | 35.45% |
2020 Q1 | 3.5 Million SEK | -6.81% |
2020 FY | 3.55 Million SEK | -5.37% |
2020 Q4 | 3.55 Million SEK | 5.97% |
2020 Q3 | 3.35 Million SEK | -9.37% |
2020 Q2 | 3.7 Million SEK | 5.74% |
2019 Q2 | 1.87 Million SEK | -11.8% |
2019 FY | 3.75 Million SEK | 8.31% |
2019 Q4 | 3.75 Million SEK | 18.35% |
2019 Q3 | 3.17 Million SEK | 69.41% |
2019 Q1 | 2.12 Million SEK | -38.75% |
2018 Q4 | 3.46 Million SEK | 112.51% |
2018 FY | 3.46 Million SEK | 35.85% |
2018 Q1 | 2.44 Million SEK | -4.4% |
2018 Q3 | 1.63 Million SEK | 133.2% |
2018 Q2 | -4.91 Million SEK | -301.42% |
2017 Q2 | 2.12 Million SEK | 0.0% |
2017 FY | 2.55 Million SEK | -5.47% |
2017 Q1 | - SEK | -100.0% |
2017 Q3 | 3.08 Million SEK | 44.98% |
2017 Q4 | 2.55 Million SEK | -17.15% |
2016 FY | 2.7 Million SEK | 4.4% |
2016 Q4 | 2.7 Million SEK | 0.0% |
2016 Q1 | - SEK | 0.0% |
2015 FY | 2.58 Million SEK | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Alligator Bioscience AB (publ) | 106.59 Million SEK | 87.158% |
Ziccum AB (publ) | 6.38 Million SEK | -114.293% |
Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -480.291% |
BioArctic AB (publ) | 139.5 Million SEK | 90.187% |
Sprint Bioscience AB (publ) | 34.6 Million SEK | 60.44% |
Mendus AB (publ) | 51.22 Million SEK | 73.277% |
Genovis AB (publ.) | 98.04 Million SEK | 86.038% |
Intervacc AB (publ) | 21.68 Million SEK | 36.859% |
QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 48.745% |
Active Biotech AB (publ) | 13.4 Million SEK | -2.157% |
Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 88.959% |
Bio-Works Technologies AB (publ) | 16.11 Million SEK | 15.064% |
Aptahem AB (publ) | 8.99 Million SEK | -52.137% |
Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 66.497% |
Kancera AB (publ) | 17.97 Million SEK | 23.857% |
Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 70.357% |
Fluicell AB (publ) | 8.91 Million SEK | -53.551% |
Saniona AB (publ) | 86.08 Million SEK | 84.098% |
Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -165.395% |
Biovica International AB (publ) | 34.76 Million SEK | 60.626% |
Spago Nanomedical AB (publ) | 11.66 Million SEK | -17.321% |
AcouSort AB (publ) | 10.37 Million SEK | -31.905% |
Xintela AB (publ) | 14.01 Million SEK | 2.326% |
Abliva AB (publ) | 16.78 Million SEK | 18.425% |
Egetis Therapeutics AB (publ) | 214.6 Million SEK | 93.621% |
Karolinska Development AB (publ) | 11.56 Million SEK | -18.325% |
OncoZenge AB (publ) | 1.69 Million SEK | -705.712% |
Amniotics AB (publ) | 10.54 Million SEK | -29.791% |
2cureX AB (publ) | 2.93 Million SEK | -366.407% |
CombiGene AB (publ) | 4.15 Million SEK | -229.381% |
Asarina Pharma AB (publ) | 4.42 Million SEK | -209.287% |
Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.126% |
Camurus AB (publ) | 414.81 Million SEK | 96.7% |
Corline Biomedical AB | 6.78 Million SEK | -101.636% |
IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 77.689% |
Isofol Medical AB (publ) | 19.16 Million SEK | 28.569% |
I-Tech AB | 16.2 Million SEK | 15.526% |
Hansa Biopharma AB (publ) | 1.18 Billion SEK | 98.846% |
Cyxone AB (publ) | 4.69 Million SEK | -191.629% |
ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -2.709% |
Biosergen AB | 5.08 Million SEK | -169.205% |
Cantargia AB (publ) | 54.97 Million SEK | 75.097% |
Xspray Pharma AB (publ) | 71.85 Million SEK | 80.948% |
Elicera Therapeutics AB (publ) | 13.77 Million SEK | 0.599% |
Nanologica AB (publ) | 79.32 Million SEK | 82.744% |
SynAct Pharma AB | 51.83 Million SEK | 73.591% |
Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -72.211% |
Stayble Therapeutics AB (publ) | 5.19 Million SEK | -163.507% |
LIDDS AB (publ) | 3.75 Million SEK | -264.458% |
Lipum AB (publ) | 7.53 Million SEK | -81.601% |
BioInvent International AB (publ) | 90.45 Million SEK | 84.866% |
Alzinova AB (publ) | 9.33 Million SEK | -46.705% |
Oncopeptides AB (publ) | 181.59 Million SEK | 92.462% |
Pila Pharma AB (publ) | 1.79 Million SEK | -663.047% |
Guard Therapeutics International AB (publ) | 18.49 Million SEK | 25.981% |
Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -256.672% |
Simris Alg AB (publ) | 148.93 Million SEK | 90.809% |
Diamyd Medical AB (publ) | 71.11 Million SEK | 80.752% |
Xbrane Biopharma AB (publ) | 482.17 Million SEK | 97.161% |
Ascelia Pharma AB (publ) | 12.74 Million SEK | -7.416% |
Diagonal Bio AB (publ) | 7.26 Million SEK | -88.554% |